Whitfield Advises TerSera Therapeutics on Sale of Infusion Specialty Therapies Business Unit to ESTEVE
Overview
The source describes Ter Sera Therapeutics’ agreement to sell its infusion-specialty therapies unit to ESTEVE.
Products involved
The business includes Prialt,ziconotide for intrathecal infusion, and Quzyttir,cetirizine hydrochloride injection.
Expected timing
The original announcement anticipated a first-quarter 2026 closing, subject to regulatory clearance.
Counsel identified
Kyle Mc Hugh, Ben Vizvary, Chris Thomas and Emily Binger are listed on corporate work, with technology, finance and tax support. The transaction record identifies products within the business being sold; it is not guidance on their clinical use, efficacy or suitability for an individual patient.
